Cyfuse Biomedical K.K. (TYO:4892)

Japan · Delayed Price · Currency is JPY

570.00

0.00 (0.00%)

Aug 27, 2026, 3:30 PM JST

Cyfuse Biomedical K.K. Financials Overview

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	305	230	54	61	374	708
Revenue Growth	369.23%	325.93%	-11.47%	-83.69%	-47.17%	416.79%
Gross Profit	164	113	16	38	241	571
Operating Income	-775	-829	-896	-697	-425	71
Net Income	-795	-763	-872	-589	-473	142
Earnings Per Share	-82.10	-86.69	-108.31	-75.39	-177.31	283.72
EPS Growth	-	-	-	-	-	-

Revenue by Segment

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Regenerative Medicine	36.68	42.9	119.9	516.14	62.08
Device	13.22	17.78	234.58	162.1	65.41
Drug Discovery Support	4.55	0.42	20	30	10

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	3,391	3,726	3,052	3,873	4,437	2,413
Total Debt	1,232	1,311	852	913	907	567
Net Cash (Debt)	2,159	2,415	2,200	2,960	3,530	1,846
Net Cash Growth	11.75%	9.77%	-25.68%	-16.15%	91.22%	19.48%
Net Cash Per Share	222.97	274.37	273.27	378.89	1323.28	3688.31

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-693	-534	-760	-562	-403	-
Capital Expenditures	-3	-47	-8	-19	-228	-
Free Cash Flow	-696	-581	-768	-581	-631	-
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	53.77%	49.13%	29.63%	62.30%	64.44%	80.65%
Operating Margin	-254.10%	-360.44%	-1659.26%	-1142.62%	-113.64%	10.03%
Pretax Margin	-260.00%	-330.87%	-1611.11%	-960.66%	-125.94%	20.34%
Profit Margin	-260.66%	-331.74%	-1614.82%	-965.57%	-126.47%	20.06%
FCF Margin	-228.20%	-252.61%	-1422.22%	-952.46%	-168.72%	-

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Aug '26 Aug 27, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PS Ratio	18.62	24.66	68.09	97.65	25.56	-